BE2011C038I2 - - Google Patents

Download PDF

Info

Publication number: BE2011C038I2
Authority: BE; Belgium

Application number

BE2011C038C

Other languages

French (fr)

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-21

Filing date

2011-10-27

Publication date

2022-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31947613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2011C038(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-21 Priority claimed from DE10238243A external-priority patent/DE10238243A1/de

2003-03-20 Priority claimed from DE10312353A external-priority patent/DE10312353A1/de

2011-10-27 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2022-08-09 Publication of BE2011C038I2 publication Critical patent/BE2011C038I2/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)

BE2011C038C 2002-08-21 2011-10-27 BE2011C038I2 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10238243A DE10238243A1 (de)	2002-08-21	2002-08-21	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10312353A DE10312353A1 (de)	2003-03-20	2003-03-20	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PCT/EP2003/009127 WO2004018468A2 (de)	2002-08-21	2003-08-18	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
BE2011C038I2 true BE2011C038I2 (pl)	2022-08-09

Family

ID=31947613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2011C038C BE2011C038I2 (pl)	2002-08-21	2011-10-27

Country Status (38)

Country	Link
EP (6)	EP2070539A1 (pl)
JP (6)	JP4233524B2 (pl)
KR (2)	KR101111101B1 (pl)
CN (4)	CN105001222B (pl)
AR (3)	AR041025A1 (pl)
AT (1)	ATE453644T1 (pl)
AU (2)	AU2003253418B2 (pl)
BE (1)	BE2011C038I2 (pl)
BR (2)	BR122012026540B8 (pl)
CA (1)	CA2496249C (pl)
CY (3)	CY1109928T1 (pl)
DE (2)	DE50312295D1 (pl)
DK (1)	DK1532149T3 (pl)
EA (3)	EA010303B1 (pl)
EC (2)	ECSP055617A (pl)
EG (1)	EG25011A (pl)
ES (1)	ES2339112T3 (pl)
FR (1)	FR11C0052I2 (pl)
HK (6)	HK1081552A1 (pl)
HR (2)	HRP20050157B1 (pl)
HU (1)	HUS1100028I1 (pl)
IL (1)	IL166964A (pl)
IN (2)	IN2015DN01132A (pl)
LU (2)	LU91889I2 (pl)
ME (1)	MEP59708A (pl)
MX (1)	MXPA05001684A (pl)
MY (2)	MY165643A (pl)
NO (4)	NO333970B1 (pl)
PE (1)	PE20040897A1 (pl)
PL (2)	PL216134B1 (pl)
PT (1)	PT1532149E (pl)
RS (2)	RS52142B (pl)
SA (1)	SA03240448B1 (pl)
SI (1)	SI1532149T1 (pl)
TW (3)	TWI469783B (pl)
UA (1)	UA84275C2 (pl)
UY (1)	UY27946A1 (pl)
WO (1)	WO2004018468A2 (pl)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR040232A1 (es) *	2002-05-31	2005-03-23	Schering Corp	Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos
GB0215293D0 (en)	2002-07-03	2002-08-14	Rega Foundation	Viral inhibitors
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4233524B2 (ja) *	2002-08-21	2009-03-04	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造およびその薬理組成物としての使用
US7569574B2 (en)	2002-08-22	2009-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en)	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en)	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) *	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
ATE462432T1 (de)	2003-05-05	2010-04-15	Probiodrug Ag	Glutaminylcyclase-hemmer
US7566707B2 (en)	2003-06-18	2009-07-28	Boehringer Ingelheim International Gmbh	Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de)	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP4970048B2 (ja)	2003-12-22	2012-07-04	カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ	イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
DE10360835A1 (de) *	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0507873B8 (pt)	2004-02-18	2021-05-25	Boehringer Ingelheim Int	8-[3-amino-piperidin-1-il]-xantinas, seu processo de produção, seu uso como inibidor de dpp-iv e medicamento
AU2012202850B2 (en) *	2004-02-18	2015-08-20	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en)	2004-03-13	2008-07-01	Boehringer Ingleheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CN102127053A (zh)	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
US7439370B2 (en)	2004-05-10	2008-10-21	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
MX2007001054A (es)	2004-07-27	2007-07-25	Gilead Sciences Inc	Imidazo[4,5-d]pirimidinas, sus usos y metodos de preparacion.
DE102004043944A1 (de) *	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de)	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2012205240B2 (en) *	2004-11-05	2015-03-26	Boehringer Ingelheim International Gmbh	Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
NZ556624A (en)	2004-12-21	2010-06-25	Gilead Sciences Inc	5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE532518T1 (de)	2005-09-14	2011-11-15	Takeda Pharmaceutical	Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
PT1931350E (pt) †	2005-09-14	2014-02-12	Takeda Pharmaceutical	Administração de inibidores de dipeptidil peptidase
KR101368988B1 (ko)	2005-09-16	2014-02-28	다케다 야쿠힌 고교 가부시키가이샤	디펩티딜 펩티다제 억제제
JP2009521430A (ja) *	2005-12-23	2009-06-04	アストラゼネカ・アクチエボラーグ	Ｇａｂａ−ｂ受容体モジュレーター
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
TW200803855A (en) *	2006-02-24	2008-01-16	Kalypsys Inc	Quinolones useful as inducible nitric oxide synthase inhibitors
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
NO347644B1 (no)	2006-05-04	2024-02-12	Boehringer Ingelheim Int	Polymorfer
EP1852108A1 (en) *	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es) *	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ATE454384T1 (de)	2006-07-07	2010-01-15	Gilead Sciences Inc	Neue pyridazinverbindung und ihre verwendung
JP2010500326A (ja) *	2006-08-08	2010-01-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2089383B1 (en)	2006-11-09	2015-09-16	Probiodrug AG	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9126987B2 (en)	2006-11-30	2015-09-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
UA99466C2 (en)	2007-07-06	2012-08-27	Гилиад Сайенсиз, Инк.	Crystalline pyridazine compound
PE20090597A1 (es) *	2007-08-16	2009-06-06	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
BRPI0815405A2 (pt) *	2007-08-17	2015-02-03	Boehringer Ingelheim Int	Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) *	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) *	2008-08-15	2014-08-29	Boehringer Ingelheim Int	Purin derivatives for use in the treatment of fab-related diseases
KR20110067096A (ko) *	2008-09-10	2011-06-21	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 및 관련 상태를 치료하기 위한 병용 요법
UY32177A (es) *	2008-10-16	2010-05-31	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) *	2008-12-23	2014-05-30	Boehringer Ingelheim Int	Salt forms of a xanthine derivative
AR074990A1 (es) *	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) *	2009-01-29	2015-01-01	Boehringer Ingelheim Int	小兒科病人糖尿病之治療
CA2752437C (en)	2009-02-13	2017-07-11	Boehringer Ingelheim International Gmbh	Antidiabetic medications
UY32427A (es) *	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BRPI1008560B1 (pt)	2009-02-13	2021-08-31	Boehringer Ingelheim International Gmbh	Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP5934645B2 (ja)	2009-09-11	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP5736377B2 (ja)	2009-09-30	2015-06-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法
KR101813025B1 (ko)	2009-09-30	2017-12-28	베링거 인겔하임 인터내셔날 게엠베하	글루코피라노실치환된 벤질벤젠 유도체의 제조방법
NZ598170A (en)	2009-10-02	2014-06-27	Boehringer Ingelheim Int	Pharmaceutical compositions comprising bi-1356 and metformin
US10610489B2 (en)	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
SG183229A1 (en)	2010-03-10	2012-09-27	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP2013522279A (ja)	2010-03-18	2013-06-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
CN102918027A (zh)	2010-04-06	2013-02-06	艾尼纳制药公司	Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
EA201201509A1 (ru)	2010-05-05	2013-04-30	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтические составы, содержащие пиоглитазон и линаглиптин
KR20130093012A (ko) *	2010-06-24	2013-08-21	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
PE20131371A1 (es)	2010-09-22	2013-11-25	Arena Pharm Inc	Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
PT2640371T (pt) *	2010-11-15	2020-04-17	Boehringer Ingelheim Int	Terapia antidiabética vasoprotetora e cardioprotetora
US9034883B2 (en) *	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US8530670B2 (en)	2011-03-16	2013-09-10	Probiodrug Ag	Inhibitors
WO2012135570A1 (en)	2011-04-01	2012-10-04	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012152837A1 (en)	2011-05-10	2012-11-15	Sandoz Ag	Polymorph of linagliptin benzoate
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3517539B1 (en)	2011-07-15	2022-12-14	Boehringer Ingelheim International GmbH	Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20130123282A1 (en)	2011-11-16	2013-05-16	Leonid Metsger	Solid state forms of linagliptin
US20130172244A1 (en)	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
CN103254193B (zh) *	2012-02-15	2015-04-22	上海医药工业研究院	黄嘌呤类化合物中间体及其制备方法
CN103254192B (zh) *	2012-02-15	2015-12-02	上海医药工业研究院	黄嘌呤类化合物、其盐、中间体、制备方法及应用
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9879011B2 (en)	2012-03-12	2018-01-30	Cadila Healthcare Limited	Amorphous form of linagliptin and process for preparation thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN103373999B (zh) *	2012-04-28	2016-01-13	上海医药工业研究院	嘌呤类化合物、中间体、制备方法及其应用
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) *	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6374862B2 (ja)	2012-05-24	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
EP2854824A1 (en)	2012-05-25	2015-04-08	Boehringer Ingelheim International GmbH	Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
CN103509022B (zh) *	2012-06-20	2015-04-01	成都苑东药业有限公司	黄嘌呤衍生物
CN103509023B (zh) *	2012-06-20	2014-08-27	成都苑东药业有限公司	黄嘌呤衍生物
ES2659563T3 (es)	2012-08-13	2018-03-16	Sandoz Ag	Composición farmacéutica estable que contiene 8-[(3R)-3-amino-1-piperidinil]-7-(2-butin-1-il)-3,7-dihidro-3-metil-1-[(4-metil-2-quinazolinil) metil]-1H-purin-2,6-diona o una sal farmacéuticamente aceptable de la misma
WO2014045266A1 (en)	2012-09-24	2014-03-27	Ulf Eriksson	Treatment of type 2 diabetes and related conditions
CN103709163B (zh) *	2012-09-29	2016-12-21	齐鲁制药有限公司	黄嘌呤衍生物、其制备方法及用途
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN103319483B (zh) *	2012-10-19	2016-08-03	药源药物化学（上海）有限公司	一种利拉列汀重要中间体的制备方法
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
WO2014097314A1 (en) *	2012-12-17	2014-06-26	Mylan Laboratories Ltd	An improved process for the preparation of linagliptin
SG11201504215PA (en)	2012-12-21	2015-06-29	Sanofi Sa	Functionalized exendin-4 derivatives
CN103936740B (zh) *	2013-01-23	2016-06-29	成都苑东生物制药股份有限公司	黄嘌呤衍生物
CN103936738B (zh) *	2013-01-23	2016-11-23	成都苑东生物制药股份有限公司	黄嘌呤衍生物
CN103936737B (zh) *	2013-01-23	2016-09-14	成都苑东生物制药股份有限公司	黄嘌呤衍生物
CN103936739B (zh) *	2013-01-23	2016-08-31	成都苑东生物制药股份有限公司	黄嘌呤衍生物
EP2970502A4 (en)	2013-03-15	2016-11-30	Dyax Corp	ANTI-PLASMA KALLIKREIN ANTIBODY
EP3744327A1 (en)	2013-03-15	2020-12-02	Boehringer Ingelheim International GmbH	Use of linagliptin in cardio- and renoprotective antidiabetic therapy
HUE041709T2 (hu)	2013-04-05	2019-05-28	Boehringer Ingelheim Int	Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl)	2013-04-18	2022-04-29	Boehringer Ingelheim International Gmbh	Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
JP6507154B2 (ja) *	2013-06-14	2019-04-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及びその合併症を治療するためのｄｄｐ−４阻害薬
CN104292228B (zh) *	2013-07-16	2016-03-30	成都苑东生物制药股份有限公司	一种黄嘌呤化合物的多晶型及其制备方法、用途
WO2015011609A1 (en)	2013-07-23	2015-01-29	Ranbaxy Laboratories Limited	Process for the preparation of linagliptin and an intermediate thereof
CN104418857A (zh) *	2013-08-22	2015-03-18	北京蓝丹医药科技有限公司	无定型利格列汀及其制备方法
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
CN104725379A (zh) *	2013-12-24	2015-06-24	杭州民生药物研究院有限公司	嘌呤酮衍生物及其组合物的制备方法与用途
JP6615109B2 (ja) *	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104557935B (zh) *	2015-01-27	2016-08-17	江苏嘉逸医药有限公司	制备(r)-8-(3-氨基哌啶-1-基)-黄嘌呤的提纯方法
CN107683135A (zh)	2015-03-09	2018-02-09	因特克林医疗有限公司	用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016207364A1 (en)	2015-06-25	2016-12-29	Boehringer Ingelheim International Gmbh	Process for the preparation of a xanthine-based compound
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10668073B2 (en)	2015-10-09	2020-06-02	Hexal Ag	Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof
EP3156048A1 (en)	2015-10-13	2017-04-19	Galenicum Health S.L.	Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
CN105566271B (zh) *	2015-12-03	2019-09-13	福建医科大学	双黄酮化合物及其制备治疗癌症的药物的用途
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin
US11285180B2 (en)	2016-12-06	2022-03-29	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2018187350A1 (en)	2017-04-03	2018-10-11	Coherus Biosciences Inc.	PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
KR102469957B1 (ko)	2017-06-30	2022-11-24	한미약품 주식회사	리나글립틴, 메트포르민 및 항산화제를 포함하는, 안정성이 개선된 약제학적 조성물
CN107325114B (zh) *	2017-07-04	2019-06-11	吉林省爱诺德生物工程有限公司	一种头孢洛林酯中间体的制备方法
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
KR102500835B1 (ko)	2017-10-24	2023-02-17	한미약품 주식회사	리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법
CN108299436B (zh) *	2018-02-09	2020-01-17	上海慈瑞医药科技股份有限公司	黄嘌呤类化合物及其药物组合物和应用
KR102208009B1 (ko) *	2018-04-26	2021-01-28	주식회사 경보제약	신규한 리나글립틴 염 화합물, 이의 제조 방법 및 신규한 리나글립틴 염 화합물로부터 제조된 리나글립틴
KR102647472B1 (ko)	2018-07-31	2024-03-14	한미약품 주식회사	디펩티딜 펩티다아제-4 억제제 및 메트포르민을 포함하는 경구용 고형 복합제제 및 이의 제조방법
HU231374B1 (hu)	2018-08-06	2023-04-28	Richter Gedeon Nyrt.	Eljárás BOC-Linagliptin előállítására
JP7413346B2 (ja)	2019-03-06	2024-01-15	第一三共株式会社	ピロロピラゾール誘導体
CN110305131B (zh) *	2019-07-03	2021-12-31	山东百诺医药股份有限公司	利格列汀新晶型及其制备方法
EP3811930A1 (en)	2019-10-24	2021-04-28	Authenda Pharmaceuticals AG	Oral gliptin compositions and method for preparation thereof
WO2021109970A1 (zh) *	2019-12-02	2021-06-10	成都苑东生物制药股份有限公司	一种黄嘌呤衍生物药物组合物及其制备方法
EP4103157A1 (en)	2020-02-13	2022-12-21	Zaklady Farmaceutyczne Polpharma S.A.	Pharmaceutical composition comprising linagliptin and metformin
CN112876409A (zh) *	2021-01-20	2021-06-01	都创(上海)医药科技股份有限公司	一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法
CN117858703A (zh)	2021-07-22	2024-04-09	新梅斯托克公司	用于制备包含利格列汀和盐酸二甲双胍的药物组合物的方法
KR20230055762A (ko)	2021-10-19	2023-04-26	한미약품 주식회사	메트포르민, 리나글립틴 및 메글루민을 포함하는 약제학적 복합제제
WO2023156675A1 (en)	2022-02-21	2023-08-24	Krka, D.D., Novo Mesto	Process for purification of linagliptin
KR20230126664A (ko)	2022-02-23	2023-08-30	주식회사 제뉴원사이언스	리나글립틴 또는 이의 약학적으로 허용가능한 염과 메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 약물방출이 조절된 약제학적 복합제제
CN114989147B (zh) *	2022-06-20	2024-05-17	广东晨康生物科技有限公司	一种苯并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
EP4349837A1 (en)	2022-10-05	2024-04-10	Zaklady Farmaceutyczne "Polpharma" S.A.	A pharmaceutical intermediate
WO2024091863A1 (en)	2022-10-25	2024-05-02	Starrock Pharma Llc	Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4061753A (en) *	1976-02-06	1977-12-06	Interx Research Corporation	Treating psoriasis with transient pro-drug forms of xanthine derivatives
FR2558162B1 (fr) *	1984-01-17	1986-04-25	Adir	Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
US4968672A (en) *	1987-01-02	1990-11-06	The United States Of America As Represented By The Department Of Health And Human Services	Adenosine receptor prodrugs
FR2654935B1 (fr) *	1989-11-28	1994-07-01	Lvmh Rech	Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5965555A (en) *	1996-06-07	1999-10-12	Hoechst Aktiengesellschaft	Xanthine compounds having terminally animated alkynol side chains
ATE297904T1 (de)	1997-04-15	2005-07-15	Genentech Inc	Halo-alkoxycarbonylverbindungen
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE60132723T2 (de) *	2000-01-21	2009-01-29	Novartis Pharma Ag	Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
GB0008694D0 (en) *	2000-04-07	2000-05-31	Novartis Ag	Organic compounds
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
EP1301187B1 (en) *	2000-07-04	2005-07-06	Novo Nordisk A/S	Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
NZ528216A (en) *	2001-02-24	2006-12-22	Boehringer Ingelheim Pharma	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
EP1404675B1 (en) *	2001-07-03	2008-03-12	Novo Nordisk A/S	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
JP2005509603A (ja) *	2001-09-19	2005-04-14	ノボ　ノルディスク　アクティーゼルスカブ	Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
EP1496877B1 (en) *	2002-01-11	2008-10-01	Novo Nordisk A/S	Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
JP4233524B2 (ja) *	2002-08-21	2009-03-04	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造およびその薬理組成物としての使用
DE10251927A1 (de) *	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel

2003
- 2003-08-18 JP JP2004530186A patent/JP4233524B2/ja not_active Expired - Lifetime
- 2003-08-18 CN CN201510299950.3A patent/CN105001222B/zh not_active Expired - Lifetime
- 2003-08-18 ES ES03792359T patent/ES2339112T3/es not_active Expired - Lifetime
- 2003-08-18 EA EA200500302A patent/EA010303B1/ru active Protection Beyond IP Right Term
- 2003-08-18 CN CN201710930674.5A patent/CN107674077A/zh active Pending
- 2003-08-18 EP EP08159141A patent/EP2070539A1/de not_active Withdrawn
- 2003-08-18 DE DE50312295T patent/DE50312295D1/de not_active Expired - Lifetime
- 2003-08-18 EA EA201001167A patent/EA024251B1/ru not_active IP Right Cessation
- 2003-08-18 DK DK03792359.6T patent/DK1532149T3/da active
- 2003-08-18 AT AT03792359T patent/ATE453644T1/de active
- 2003-08-18 UA UAA200502487A patent/UA84275C2/ru unknown
- 2003-08-18 EP EP08161656A patent/EP2060573A3/de not_active Withdrawn
- 2003-08-18 SI SI200331782T patent/SI1532149T1/sl unknown
- 2003-08-18 CA CA2496249A patent/CA2496249C/en not_active Expired - Lifetime
- 2003-08-18 MX MXPA05001684A patent/MXPA05001684A/es active IP Right Grant
- 2003-08-18 ME MEP-597/08A patent/MEP59708A/xx unknown
- 2003-08-18 BR BR122012026540A patent/BR122012026540B8/pt active IP Right Grant
- 2003-08-18 EA EA200702022A patent/EA016166B1/ru active Protection Beyond IP Right Term
- 2003-08-18 EP EP08159140A patent/EP2058311A3/de not_active Withdrawn
- 2003-08-18 EP EP03792359A patent/EP1532149B9/de not_active Expired - Lifetime
- 2003-08-18 EP EP18185103.1A patent/EP3424926A1/de not_active Withdrawn
- 2003-08-18 RS YU20050137A patent/RS52142B/sr unknown
- 2003-08-18 PT PT03792359T patent/PT1532149E/pt unknown
- 2003-08-18 BR BRPI0313648A patent/BRPI0313648B8/pt active IP Right Grant
- 2003-08-18 EP EP10185171A patent/EP2308878A3/de not_active Withdrawn
- 2003-08-18 RS RS20120139 patent/RS20120139A3/en unknown
- 2003-08-18 WO PCT/EP2003/009127 patent/WO2004018468A2/de active Application Filing
- 2003-08-18 KR KR1020097008185A patent/KR101111101B1/ko active IP Right Review Request
- 2003-08-18 CN CN201210423313.9A patent/CN102964347B/zh not_active Expired - Lifetime
- 2003-08-18 PL PL375342A patent/PL216134B1/pl unknown
- 2003-08-18 AU AU2003253418A patent/AU2003253418B2/en active Active
- 2003-08-18 KR KR1020057002834A patent/KR101150449B1/ko active IP Right Review Request
- 2003-08-18 CN CNB03819760XA patent/CN100522962C/zh not_active Expired - Lifetime
- 2003-08-18 PL PL403104A patent/PL403104A1/pl unknown
- 2003-08-19 MY MYPI20083230A patent/MY165643A/en unknown
- 2003-08-19 PE PE2003000838A patent/PE20040897A1/es active IP Right Grant
- 2003-08-19 EG EG2003080818A patent/EG25011A/xx active
- 2003-08-19 MY MYPI20033150A patent/MY137619A/en unknown
- 2003-08-20 TW TW101137343A patent/TWI469783B/zh not_active IP Right Cessation
- 2003-08-20 TW TW092122890A patent/TWI319320B/zh active
- 2003-08-20 TW TW098125780A patent/TWI388325B/zh not_active IP Right Cessation
- 2003-08-20 AR ARP030103009A patent/AR041025A1/es active IP Right Grant
- 2003-08-21 UY UY27946A patent/UY27946A1/es not_active IP Right Cessation
- 2003-12-17 SA SA03240448A patent/SA03240448B1/ar unknown
2005
- 2005-01-06 NO NO20050069A patent/NO333970B1/no not_active IP Right Cessation
- 2005-02-17 IL IL166964A patent/IL166964A/en active Protection Beyond IP Right Term
- 2005-02-18 EC EC2005005617A patent/ECSP055617A/es unknown
- 2005-02-18 HR HR20050157 patent/HRP20050157B1/xx not_active IP Right Cessation
2006
- 2006-02-16 HK HK06101985.9A patent/HK1081552A1/xx not_active IP Right Cessation
2008
- 2008-06-11 JP JP2008152875A patent/JP4971251B2/ja not_active Expired - Lifetime
- 2008-10-16 JP JP2008267827A patent/JP5351486B2/ja not_active Expired - Lifetime
2009
- 2009-12-14 HR HR20090665A patent/HRP20090665A2/hr active Application Revival
2010
- 2010-01-28 HK HK10100904.3A patent/HK1134077A1/xx not_active IP Right Cessation
- 2010-01-28 HK HK10100903.4A patent/HK1134076A1/xx not_active IP Right Cessation
- 2010-03-22 CY CY20101100275T patent/CY1109928T1/el unknown
- 2010-04-07 AU AU2010201384A patent/AU2010201384C1/en active Active
- 2010-08-13 AR ARP100102982A patent/AR077875A2/es active Pending
2011
- 2011-10-21 LU LU91889C patent/LU91889I2/fr unknown
- 2011-10-27 BE BE2011C038C patent/BE2011C038I2/fr unknown
- 2011-11-03 DE DE201112100059 patent/DE122011100059I1/de active Pending
- 2011-11-29 FR FR11C0052C patent/FR11C0052I2/fr active Active
- 2011-12-15 HU HUS1100028C patent/HUS1100028I1/hu unknown
2012
- 2012-01-13 CY CY2012001C patent/CY2012001I2/el unknown
- 2012-03-06 EC ECSP12005617 patent/ECSP12005617A/es unknown
- 2012-04-11 JP JP2012090295A patent/JP5623459B2/ja not_active Expired - Lifetime
- 2012-07-23 AR ARP120102668A patent/AR087287A2/es active Pending
2013
- 2013-01-08 CY CY2013002C patent/CY2013002I1/el unknown
- 2013-01-09 LU LU92128C patent/LU92128I2/fr unknown
- 2013-07-12 NO NO20130968A patent/NO20130968L/no not_active Application Discontinuation
- 2013-08-18 IN IN1132DEN2015 patent/IN2015DN01132A/en unknown
- 2013-08-18 IN IN1133DEN2015 patent/IN2015DN01133A/en unknown
- 2013-09-09 HK HK13110418.8A patent/HK1183028A1/zh not_active IP Right Cessation
2014
- 2014-02-24 NO NO20140234A patent/NO336641B1/no not_active IP Right Cessation
- 2014-04-08 NO NO2014008C patent/NO2014008I1/no unknown
- 2014-05-26 JP JP2014108575A patent/JP6114231B2/ja not_active Expired - Lifetime
2016
- 2016-03-24 HK HK16103474.1A patent/HK1215439A1/zh not_active IP Right Cessation
- 2016-07-04 JP JP2016132807A patent/JP6139004B2/ja not_active Expired - Lifetime
2018
- 2018-08-02 HK HK18109982.1A patent/HK1250708A1/zh unknown

Also Published As

Publication number	Publication date
AR041025A1 (es)	2005-04-27
TWI319320B (en)	2010-01-11
CA2496249A1 (en)	2004-03-04
EP2060573A3 (de)	2011-04-13
DE50312295D1 (de)	2010-02-11
JP2012162555A (ja)	2012-08-30
TWI469783B (zh)	2015-01-21
NO20130968L (no)	2005-03-03
RS20050137A (en)	2007-11-15
ME00396B (me)	2011-05-10
CN1675212A (zh)	2005-09-28
HK1215439A1 (zh)	2016-08-26
EP3424926A1 (de)	2019-01-09
LU91889I9 (pl)	2019-01-03
CN100522962C (zh)	2009-08-05
EA010303B1 (ru)	2008-08-29
EP2058311A3 (de)	2011-04-13
DE122011100059I1 (de)	2012-04-05
EG25011A (en)	2011-05-25
KR101150449B1 (ko)	2012-06-01
NO2014008I1 (no)	2014-06-02
HK1250708A1 (zh)	2019-01-11
JP4233524B2 (ja)	2009-03-04
KR101111101B1 (ko)	2012-06-13
JP2009001565A (ja)	2009-01-08
IN2015DN01132A (pl)	2015-06-26
CY2012001I1 (el)	2016-12-14
AR087287A2 (es)	2014-03-12
EP2308878A3 (de)	2011-10-26
JP5351486B2 (ja)	2013-11-27
JP6114231B2 (ja)	2017-04-12
UA84275C2 (ru)	2008-10-10
EP2070539A1 (de)	2009-06-17
HK1134076A1 (pl)	2010-04-16
HUS1100028I1 (hu)	2016-07-28
ECSP055617A (es)	2005-05-30
HRP20050157B1 (en)	2013-01-31
ECSP12005617A (es)	2012-04-30
EA201001167A1 (ru)	2011-02-28
PT1532149E (pt)	2010-02-17
RS20120139A2 (en)	2012-10-31
LU92128I2 (fr)	2013-03-11
AU2010201384C1 (en)	2013-09-26
CY1109928T1 (el)	2014-09-10
HRP20050157A2 (en)	2006-05-31
AU2010201384A1 (en)	2010-04-29
CN105001222A (zh)	2015-10-28
JP2009079061A (ja)	2009-04-16
MY165643A (en)	2018-04-18
EA200500302A1 (ru)	2005-10-27
JP2006503013A (ja)	2006-01-26
TW200404542A (en)	2004-04-01
EP2308878A2 (de)	2011-04-13
PL403104A1 (pl)	2013-05-13
AU2003253418A1 (en)	2004-03-11
CN102964347A (zh)	2013-03-13
TW201304782A (zh)	2013-02-01
NO20050069L (no)	2005-03-03
ES2339112T3 (es)	2010-05-17
IN2015DN01133A (pl)	2015-06-26
IL166964A (en)	2011-02-28
JP2014177485A (ja)	2014-09-25
AU2010201384B2 (en)	2013-05-02
CY2013002I1 (el)	2020-05-29
KR20050058375A (ko)	2005-06-16
AR077875A2 (es)	2011-09-28
PL375342A1 (pl)	2005-11-28
CN102964347B (zh)	2015-11-18
HK1081552A1 (en)	2006-05-19
FR11C0052I1 (pl)	2012-01-06
PE20040897A1 (es)	2005-01-31
WO2004018468A2 (de)	2004-03-04
KR20090047560A (ko)	2009-05-12
PL216134B1 (pl)	2014-03-31
JP5623459B2 (ja)	2014-11-12
EA200702022A1 (ru)	2008-06-30
AU2003253418B2 (en)	2010-04-22
RS20120139A3 (en)	2015-02-27
BR122012026540B8 (pt)	2021-05-25
HK1134077A1 (en)	2010-04-16
FR11C0052I2 (fr)	2013-01-11
HRP20090665A2 (hr)	2010-07-31
MY137619A (en)	2009-02-27
EA024251B1 (ru)	2016-08-31
EP1532149B9 (de)	2011-04-20
SA03240448B1 (ar)	2009-06-07
CN107674077A (zh)	2018-02-09
JP6139004B2 (ja)	2017-05-31
NO336641B1 (no)	2015-10-12
EP1532149B1 (de)	2009-12-30
SI1532149T1 (sl)	2010-05-31
DK1532149T3 (da)	2010-05-10
BRPI0313648B1 (pt)	2018-07-17
EP2060573A2 (de)	2009-05-20
WO2004018468A3 (de)	2004-04-08
RS52142B (sr)	2012-08-31
EA016166B1 (ru)	2012-02-28
MEP59708A (en)	2011-05-10
TWI388325B (zh)	2013-03-11
MXPA05001684A (es)	2005-04-19
BR0313648A (pt)	2007-05-08
ATE453644T1 (de)	2010-01-15
NO2014008I2 (no)	2014-04-08
CN105001222B (zh)	2017-11-07
NO20140234L (no)	2005-03-03
JP4971251B2 (ja)	2012-07-11
CY2012001I2 (el)	2016-12-14
JP2016199572A (ja)	2016-12-01
EP2058311A2 (de)	2009-05-13
NO333970B1 (no)	2013-11-04
EP1532149A2 (de)	2005-05-25
UY27946A1 (es)	2004-03-31
LU91889I2 (fr)	2011-12-21
CA2496249C (en)	2012-01-24
TW200944209A (en)	2009-11-01
BR122012026540B1 (pt)	2019-04-24
BRPI0313648B8 (pt)	2021-05-25
HK1183028A1 (zh)	2013-12-13

Publication	Publication Date	Title
BE2019C547I2 (pl)	2022-05-17
BE2019C510I2 (pl)	2022-05-19
BE2018C021I2 (pl)	2023-03-07
BE2017C049I2 (pl)	2022-08-09
BE2017C005I2 (pl)	2022-05-17
BE2016C069I2 (pl)	2022-05-17
BE2016C040I2 (pl)	2022-05-17
BE2016C013I2 (pl)	2022-05-17
BE2015C078I2 (pl)	2022-08-09
BE2016C002I2 (pl)	2023-03-07
BE2018C018I2 (pl)	2023-03-07
BE2015C017I2 (pl)	2022-09-22
BE2014C053I2 (pl)	2022-08-30
BE2014C051I2 (pl)	2022-08-09
BE2014C041I2 (pl)	2022-08-09
BE2014C030I2 (pl)	2022-08-09
BE2014C016I2 (pl)	2023-03-07
BE2014C015I2 (pl)	2022-08-09
BE2013C063I2 (pl)	2023-03-07
BE2013C039I2 (pl)	2023-03-07
FR11C0052I1 (pl)	2012-01-06
BE2015C067I2 (pl)	2024-08-08
BRPI0215435A2 (pl)	2004-12-14
BE2013C046I2 (pl)	2022-08-09
JP2003156245A5 (pl)	2008-06-19